Kidney Cancer

FDA grants nivolumab/cabozantinib combo priority review in kidney cancer

October 19, 2020

The FDA is reviewing data from the phase 3 CheckMate-9ER trial, which showed that the combination significantly improved progression-free and overall survival compared with sunitinib in frontline renal cell carcinoma.

FDA issues draft guidance for adjuvant trials in bladder cancer, renal cell carcinoma

October 02, 2020

"Currently, there is significant variability in the design, conduct, and analysis of clinical trials for adjuvant treatment of both kidney cancer and bladder cancer. This variability negatively affects our ability to interpret trial results," said Richard Pazdur, MD.